{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-046948","form_type":"8-K","ticker":"KYNB","cik":"0000921299","company_name":"KYNTRA BIO, INC.","filed_at":"2025-03-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:06.816748+00:00","generated_at":"2026-05-24T03:31:53.131919+00:00","sec_items":["1.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"FibroGen and Fortis amend agreements, extend option exercise deadline to Dec 31, 2027","bullets":["Amendments No.1 to Evaluation Agreement and Option Agreement & Plan of Merger executed March 28, 2025.","Original agreements dated June 6, 2024, as amended and restated from May 5, 2023.","Option exercise deadline under both agreements extended to December 31, 2027.","Full text of amendments to be filed with FibroGen's Q1 2025 10-Q."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-046948","json":"https://secwatch.observer/filing/0000950170-25-046948.json","markdown":"https://secwatch.observer/filing/0000950170-25-046948.md","text":"https://secwatch.observer/filing/0000950170-25-046948.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/921299/000095017025046948/0000950170-25-046948-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/921299/000095017025046948/fgen-20250328.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T03:31:53.131919+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}